Objective: Previous experiments have shown that addition of fragmented fibronectin can induce cartilage chondrolysis. In this study we investigated the fate of the collagen-and cell-binding molecules Cartilage oligomeric matrix protein (COMP) and chondroadherin.
Introduction
Joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA) affect a large proportion of the population. Despite extensive research regarding the cause and mechanisms of tissue involvement in these diseases, key elements remain largely unknown. Consequently diagnostic tools routinely used today are insensitive to the early events in tissue damage, processes which could predict and may determine the course of disease.
Studies on RA suggest a dichotomous nature of the disease. On one hand there is the inflammatory component, often with extra-articular symptoms, and on the other hand the progressive destruction of joint tissues 1 . Recent therapy for RA has focused upon the blocking of cytokine pathways, particularly of tumour necrosis factor (TNF-) (for review see 2, 3 ). The anti-TNF treatment in RA relieves symptoms in some two thirds of the patients by inhibiting the inflammatory component. However, although the destruction of cartilage appears inhibited, this occurs only after a lag time 4 , indicating indirect effects. How these two processes of inflammation and destruction interrelate and possibly regulate each other is not clear. One hypothesis is that proteolytic fragments formed in the destruction process may promote further destruction of the cartilage. Analyses of joint fluid from RA patients have revealed elevated levels of inflammatory cytokines [5] [6] [7] , immunoglobulins 8, 9 and understandably, elevated levels of degraded extracellular matrix components originating from cartilage and bone. One such extracellular matrix component is fibronectin 10 . Fibronectin is found throughout the body's extracellular matrices and is particularly prominent in blood. It is a classical example of a protein with a modular structure, containing several functional domains. These can readily be separated from each other by proteolysis. The domains thus separated will retain their functionality in isolation (see 11 and references therein). In addition, these isolated domains have been shown to modulate the ability of other domains to influence cell activities 12 . Synthesis of fibronectin is up-regulated in cartilage in OA and RA, and proteolytic fragments have been identified in patients (for review see 13 ) . Pivotal experiments on functional characteristics of fragments of fibronectin generated by in vitro proteolysis were performed by Homandberg et al 14 . Proteolytic fragments of Fn were added to bovine explant cartilage cultures and shown to induce the degradation of cartilage, as monitored by the release of matrix metalloproteinases (MMPs) and proteoglycans to the medium. The intact protein did not induce these effects. The study demonstrated that proteolytic processing of extracellular matrix components may produce fragments with properties very different from the parent molecule and that these most likely contribute to the ongoing process of destruction, supporting the hypothesis outlined above.
Cartilage as a tissue is characterized by an extensive extracellular matrix. This matrix is synthesised and maintained by a single cell type, the chondrocyte, which sparsely populates it. The matrix is a fibrous collagen network that enmeshes the large aggregating proteoglycan, aggrecan. The extreme fixed negative charge conferred upon the tissue by aggrecan via its glycosaminoglycan side chains acts to retain and imbibe water, while the collagen fibre network resists any swelling of the tissue. The result is a structure capable of efficiently withstanding and distributing load. The integrity of both these structures is necessary for adequate tissue function.
Disease that progressively affects the cartilage of a joint will lead to the degradation of the major proteoglycan, aggrecan 15 at an early stage. Conversely, loss of the integrity of the collagen network appears to be a later, and perhaps more critical event 16 . Studies suggest that up to a point, aggrecan lost can be replaced. Indeed, in reactive arthritis, an acute, resolvable joint disease, levels of proteoglycans released from the articular cartilage into the synovial fluid increase to high levels and then decrease upon healing 17 . The organization of the collagen network is modulated and maintained by the many accessory molecules binding to collagen (for references see 18 ). These proteins may bind the collagen fibre, and may facilitate or prevent interactions with other collagen fibres in the network (e.g. decorin 19 , biglycan 20 , fibromodulin 21 and collagen IX 22 ). These accessory molecules also interact with a range of other extracellular matrix components, as well as cell surface receptors e.g. integrins (e.g. chondroadherin 23 ) and heparan sulphate proteoglycans (e.g. PRELP 24 ). In this manner these accessory molecules may serve to link the collagen network to the chondrocyte.
In this study, we present data that expands the concept of chondrolysis induced by extracellular matrix fragments, to include information on the fate of molecules contributing to the collagen network integrity. We show that Fn-f causes not only loss of proteoglycan, but also induces the degradation and/or release of at least two molecules primarily present in two different compartments, COMP and chondroadherin. This information supports the hypothesis that proteolytic fragments of matrix constituents can augment the destruction of cartilage, and furthers our knowledge on potential mechanisms underlying that destruction.
Materials and methods
Both Fn-f Hep I and Fn-f Hep II are purified proteolytic fragments derived from human plasma fibronectin. The Fn-f Hep II may vary at its C-terminal end, probably due to manufacturing procedures. We have found that some preparations contain the adjoining IIICS segment while others do not. This segment contains the cell-binding sequences LDV 25 and REDV 26 . By mass spectrometry we did not detect peptides from the CSIII region in the preparations that were used in the experiments. Fig. 1 .
To verify identity and determine purity, aliquots of Fn-f Hep II and Hep I were digested with trypsin and the resulting peptides analysed by MALDI-TOF mass spectrometry using standard protocols.
The porcine mucosal heparin, culture tested, was from Sigma. N-iminoethyl -lornithine (L-NIO) was from Calbiochem (U.S.A.). Dulbecco's minimal Essential medium, 100× Minimum essential amino acids, Penicillin/ Streptomycin and L-Glutamine were purchased from GIBCO Life. Polymixin B sulphate was from Sigma. Calphostin C, Herbimycin A and LNIO were from Calbiochem.
Western blots were performed using the Bio-Rad system. Membranes used were Hybond C from Amersham Life Sciences.
EXPLANT CULTURES
Cartilage was dissected from the metacarpophalangeal joint of horses aged 4-5 years. Full depth slices of cartilage were diced and mixed to randomise. Cartilage was cultured at 37 o C under an atmosphere of 5% CO 2 in serumfree DMEM supplemented with 100 Units/ml Penicillin/ Streptomycin, 1× essential amino acids and 2 mM L-Glutamine. Polymyxin B was included in medium at a concentration of 5 µg/ml.
The explant cultures were pre-incubated for 48 or 72 h to allow adaptation to culture conditions, with medium changed every 24 h. Cultures were then stimulated by the addition of Fn-f to the culture media, at a final concentration of 0.1 −1.0 µM for 48 or 72 h. In all cases the medium was changed and the stimulus renewed at 24 h intervals. In experiments with Fn-f in the presence and absence of heparin, tissue explants were treated for 72 h after preincubation. In these experiments the explants were incubated in fresh media containing 100 µg/ml heparin for 1.5 h prior to the addition of the Fn-f. This procedure was repeated with each medium change.
In experiments using inhibitors, the tissue explants were treated for 48 h after pre-incubation. The protein kinase C inhibitor Calphostin C was used at 1 µM and the Src inhibitor Herbimycin A was used at 5 µM. The iNOS inhibitor L-NIO was used at concentration of 1 mM. The inhibitors were added concomitantly with the Fn-f to see effect, or on their own to parallel cultures as controls. Fn-f was used at 200 nM in Calphostin C and Herbimycin A experiments, and at 1.0 µM concentration in L-NIO experiments.
The media were recovered and stored at −20 o C until further analysis with no further treatment. After each experiment the wet weight of the cartilage was determined before storage at −20 o C.
SDS-PAGE AND WESTERN BLOTS
Media from triplicate samples were pooled and volumes were adjusted to represent equal weights of cartilage. The
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A. Johnson et al.: COMP and CHAD in chondrolysis samples were electrophoresed under reducing as well as non-reducing conditions on 4-16% gradient SDSPolyacrylamide mini-gels 27 . Western blotting 28 was performed using the Bio-Rad system. Gels were blotted for 90 mins at 100 V. Membranes were probed with primary antibody raised in rabbit (see below), followed by a swineanti-rabbit secondary antibody conjugated to horseradish peroxidase (DAKO). Bands were visualised using enhanced chemiluminescence substrate by a method modified from that of Thorpe et al 29 .
In some experiments Western blots were probed with a polyclonal antibody against COMP followed by a polyclonal antibody against chondroadherin (see Fig. 2D ). These two antibodies do not react with the same antigens as shown by blots of articular cartilage extracts (Fig. 2D ). Sequential blotting circumvented the stripping of membranes, a procedure where protein may be lost from the membrane.
ANTIBODIES
Chondroadherin was detected with a polyclonal antibody against the bovine protein 30 . A polyclonal antibody against bovine COMP 31 was used. Both were shown to detect the corresponding equine proteins (data not shown). The anti C-terminal COMP antibody was raised against a peptide of the ten most C-terminal amino acid residues of equine COMP, which was coupled to keyhole limpet hemocyanin using standard protocols. This antibody was shown to react with equine COMP in Western blots (data not shown). In Western blots, the two polyclonal antibodies were used at a dilution of 1:1000 in block buffer (Tris-buffered The COMP content of conditioned media was determined using an inhibition ELISA 32, 33 employing equine tendon COMP as standard and a polyclonal anti-equine COMP antibody for detection. The concentration of COMP was calculated from the standard curve, and normalized to the wet weight of the cultured cartilage.
GLYCOSAMINOGLYCAN ASSAY
The release of glycosaminoglycans was analysed using the dimethylene blue assay 34 .
MASS SPECTROMETRY OF PROTEINS RELEASED INTO THE MEDIA
Aliquots of medium equalized on the basis of wet weight of the cultured cartilage were separated by SDS-PAGE and stained by Coomassie Blue. Protein bands that increased after addition of Fn-f Hep II were cut out and identified by MALDI-TOF mass spectrometry after trypsin digestion using standard protocols.
GRIESS ASSAY
The nitric oxide content of conditioned media was determined by the Griess reagent assay 35 .
DATA ANALYSIS Experiments were performed with triplicate wells, and data analysis of each well was performed in triplicate. Experiments have been repeated several (2-10) times. All experiments included positive (treatment with Fn-f Hep I) and negative (no additions) controls. Results relative to these controls were consistent and reproducible. Graphs are based on one representative experiment, and error bars indicate standard deviation of the mean.
Results
MALDI-TOF mass spectrometry identified the fibronectin fragments and matched the sequence for respective domains (coverage indicated in Fig. 1B and C) . No contaminants were detected. Interestingly, despite published data to the contrary 36 , peptides from the adjoining CSIII domain could not be detected. A preparation from a different supplier did contain such peptides (data not shown). This preparation was not used. While the preparation of Fn-f Hep II appeared to contain contaminants from the Hep I domain (underlined in Fig. 1B) , the Fn-f Hep I preparation did not contain any peptides from Hep II.
Cartilage explants prepared as described and subjected to freeze-thaw cycles before being placed in culture, did not release the components upon stimulation, as determined per Western blot (data not shown).
SDS-PAGE and mass spectrometry were used to identify components released to the medium upon stimulation with Fn-f Hep II. Matrix metalloproteases MMP-1 and MMP-3 were identified as two such components (data not shown).
The most prominent band on Coomassie-stained gels was identified as COMP by trypsin digestion and mass spectrometry (data not shown). Results in Fig. 2A and B are from experiments where cultures were treated for 48 h with the Fn-f, and the data from the last 24 h of treatment. Release of COMP quantified by ELISA ( Fig. 2A) was shown to be dose-dependent. The release of glycosaminoglycans was dose-dependent (Fig. 2B) , while rates of proteoglycan synthesis remained constant in non-stimulated culture as determined in initial experiments by [ 35 S]-sulphate incorporation (data not shown). Fig. 2D illustrates the release/degradation process over time at the dose of 250 nM. Cultures were stimulated for three days with Fn-f (days 4, 5 and 6) and medium corresponding to release from 16.5 mg explant was separated on 4-15% SDS-polyacrylamide gels. Western blots revealed that a large proportion of the COMP released was degraded (see Fig. 2D ). This degradation was dosedependent and increasing concentrations of Fn-f lead to the appearance of additional yet smaller bands (data not shown) presumably resulting from the further degradation of the larger fragments.
At initiation of culture (Days 1 to 3 of pre-culture, Fig. 2D ) we noted the release of some intact COMP (Fig. 2D , white arrow), as well as some fragmented and monomeric COMP (indicated by a light arrowhead and a bold arrowhead respectively, in Fig. 2D ). After several days in culture, these bands are no longer detectable (Day 5 and 6 Controls). Only smaller amounts of pentameric COMP retained as a complex at the top of the gel may be detected at these later time points. Addition of the Fn-f Hep II resulted in an immediate (within 24 h) and progressive release of degraded COMP as seen on Days 4, 5 and 6 of stimulation.
Western blots of both non-reduced (NR) and reduced (Red) gels consistently showed a band never seen in controls, and always seen in Fn-f Hep II treated samples. This band appears slightly smaller in size than monomer in both NR and Red gels (indicated in Fig. 2F and G by arrowhead). Though non-reduced gels were found to be particularly useful for gaining an overall picture of the total fragmentation of COMP, the appearance of the distinctive band just below the position of the monomer was often more clearly demonstrated using reduced gels. Reduced gels also provided a better estimation of the relative proportion of degraded COMP. Fig. 2F and G show the same samples (from day 6) run on NR and Red gels respectively probed with the same antibody.
In order to determine if the degradation of COMP was at one end, duplicate Western blots were probed with antibodies raised against the C-terminal and the whole protein respectively (Fig. 2E and F) . The C-terminal antibody recognized the same bands as the polyclonal antibody, with the exception of the fastest migrating bands in Fn-f treated sample, which was not detected. These bands thus lack the C-terminal part, while the other bands represent components cleaved only at the N-terminus.
OTHER MATRIX MOLECULES ARE ALSO RELEASED
Analysis using SDS-PAGE in combination with mass spectrometry identified a second collagen binding extracellular matrix molecule, chondroadherin, that was released at increased levels after stimulation with the Fn-f Hep II (Fig. 2C , incubation three days with Fn-f, sample corresponding to the last day of incubation).
While it is clear that chondroadherin was released in a dose-dependent manner (Fig. 2C) , the release over time differed from that of COMP. In contrast to COMP, chondroadherin was released in intact form, as demonstrated by SDS-PAGE and Western blots (Fig. 2D ).
FN-F HEP II INDUCES PRODUCTION OF NO
In our experiments, stimulation with Fn-f Hep II also produced NO in a dose-dependent manner (Fig. 3A) . Cultures were stimulated for two days with Fn-f, data is from last day of incubation. Use of L-NIO, an inhibitor of inducible nitric oxide synthase (iNOS) at 1 mM blocks NO production efficiently (Fig. 3B ) but has no effect on the release (Fig. 3B) and degradation (not shown) of COMP. This suggests that COMP fragmentation is parallel to, but not dependent on the production of NO.
STIMULATION WITH OTHER EXTRACELLULAR MATRIX COMPONENTS DOES NOT MIMIC FN-F
In order to determine whether the response elicited by the Fn-f Hep II was specific or merely a general distress response, explant cultures were incubated with other isolated structures relevant to the extracellular matrix of cartilage. These structures were chosen to contain domains with activities analogous to those of domains found in fibronectin. Explant cultures were incubated for 48 h with these structures, and the medium was changed and stimulus renewed after 24 h.
Thus, 1 mM concentrations of a peptide (GRGDSP) which represents the binding site of fibronectin to the 5 1 integrin did not stimulate release or degradation of COMP; neither did it stimulate NO production. Heparinbinding PRELP 37 at 1 µM (30 µg/ml), or v 3-binding Osteopontin 38 at 12 nM (400 ng/ml) showed no effect (data not shown).
Attempts were made to inhibit the effects of added fragment by pre-incubation with heparin (Fig. 4) . In experiments where cartilage explants were pre-incubated with 100 µg/ml heparin for 1.5 h prior to the addition of the Fn-f Hep II, COMP release measured by ELISA was reduced to intermediate levels as compared to Fn-f Hep II alone at the same time point (Fig. 4C) . For example, on day 5 levels of COMP released were reduced from 1145 µg/ml/g wet weight in Fn-f Hep II treated to 790 µg/ml/g wet weight in cultures treated with both Fn-f Hep II and heparin (Fig. 4C) .
The decrease of fragmentation is most clearly seen on Western blots of samples of reduced samples ( Fig. 4A and  B) . At the same time, production of NO is also decreased (Fig. 4D ).
THE N-TERMINAL FN-F HEP I SHOW ONLY PARTIAL EFFECTS
We repeated the experiments performed with Fn-f Hep II using the N-terminal fragment of fibronectin containing the Hep I domain (Fn-f Hep I) (Fig. 5) . Western blots of the conditioned media show that this fragment also induced the release and degradation of COMP (Fig. 5D ), but in these experiments this fragment was less potent than the Fn-f Hep II fragment on a molar basis (Fig. 5A) . The release of COMP was dose-dependent as shown by Western blots. The fragmentation of COMP resulted in the appearance of the signature fragment just below the monomer (Fig. 5D ) also observed in experiments with Fn-f Hep II. Hep I also induced the release of chondroadherin, but did not seem to be dose-dependent at these concentrations (Fig. 5B) . In striking contrast to results with Fn-f Hep II, the Fn-f Hep I failed to induce NO production (Fig. 5C ).
HERBIMYCIN A INHIBITS DEGRADATION OF COMP
In order to investigate which signaling pathways might be involved in transducing the effect of the Fn-f Hep II, experiments were performed where explant cultures were co-stimulated with Fn-f Hep II and a known kinase inhibitor. Media corresponding to release from 10.4 mg cartilage explant tissue was separated on 4-16% mini-gels under non-reducing conditions.
The inhibitor Calphostin C (1 µM) is an inhibitor of PKC kinases. Co-incubation of this compound with Fn-f Hep II stimulated cultures did not inhibit the release and fragmentation of COMP. Co-incubation with 5 µM Herbimycin A, an irreversible inhibitor of Src-kinases diminished the degradation of COMP (Fig. 6) . However, the release of chondroadherin did not appear to be affected in either case.
Control experiments, where Fn-f was added with DMSO (the solvent in which the inhibitors were dissolved) did not show inhibition of the Fn-f effect. Experiments where the inhibitor was added alone did not appear different from 
Discussion
Our experiments demonstrated the chondrolytic effect of two fibronectin fragments in an equine cartilage explant system. We have focused on the fate of two molecules not previously studied, namely COMP and chondroadherin.
These molecules are particularly relevant since they are involved in maintaining the integrity of the collagen network in cartilage. In cartilage destruction, it is conceivable that the ultimate degradation of the collagen network would involve an early degradation and/or release of such components.
THE RELEASE OF PROTEOGLYCAN
The release of proteoglycan in our system is in keeping with the results found for other fibronectin fragments in a bovine system. The release of proteoglycans from bovine explant articular cartilage cultures has been previously shown to be a process requiring cell activity, since freezethaw treatment precluded the process 14 . This is also the case for the extracellular matrix constituents in the current experimental set-up with Hep II stimulation (data not shown).
THE RELEASE OF COMP
A major component released into the medium from the cartilage stimulated with the Fn-f Hep II fragment was COMP as shown by SDS-PAGE/mass spectrometry. Interestingly, COMP is released from affected cartilage in joint disease in RA as well as OA. Both synovial fluid and serum levels of COMP are elevated in these diseases [39] [40] [41] . COMP is present in certain tissues e.g. blood vessels 42 and tendon 43 , but is particularly abundant in cartilage extracellular matrix 31 . It is a large (5×87 kDa) homopentameric protein, where the 5 monomers are joined at their N-termini, leaving the C-terminal globular domains free to associate with other extracellular matrix components 44 . This structure is highly suggestive of a function in linking other structures via interactions with the five identical C-terminal globular domains. It has been shown that COMP binds collagen with its C-terminal globular domains 45 . COMP appears to accelerate collagen fibrillogenesis in vitro by binding several collagen molecules, thereby contributing to the assembly of the collagen scaffolding of cartilage. (Rosenberg, Mö rgelin, Heinegå rd, unpublished).
The fragmented COMP that we demonstrated here in Fn-f stimulated cultures are monomerical and therefore lack this catalytical activity. In some cases these fragments also lack the C-terminal collagen-binding domain. Thus, they are unlikely to be able to contribute to the collagen fiber network stability and may not be able to promote and/or sustain attempts to repair it. This may be an early step contributing to the disintegration of cartilage.
THE RELEASE OF CHONDROADHERIN
In the analysis of the conditioned media from experiments by SDS-PAGE/proteolysis/mass spectrometry, we discovered that a second collagen-binding ECM protein was being released. This protein, chondroadherin, is a small 38-kDa leucine rich repeat (LRR) protein and is primarily found in cartilage, where it is concentrated pericellularly and in the territorial matrix 46 . Chondroadherin binds cells via their 2 1 integrins 23 and also binds collagen with high affinity 47 . With its multiple affinities including its cell-binding activity, chondroadherin is uniquely positioned to relay information from the surrounding matrix to the cell. Chondroadherin has not yet been implicated in joint disease, and neither intact nor fragmented chondroadherin have been found in synovial samples of RA and/or OA patients. Preliminary data indicate that already in early stages of osteoarthritis, chondroadherin levels are decreased in the articular cartilage (Må nsson, Lorenzo and Heinegå rd unpublished). In IL-1-treated bovine explant cultures chondroadherin stores are completely depleted after 12 days of culture (Heathfield, Må nsson and Heinegå rd, unpublished results). In further support for the implication of chondroadherin in cartilage pathology, treating explant cultures with APMA to activate endogenous pro-metalloproteases induced release of chondroadherin molecules attached to collagen II to the medium, but only in intact form 47 . In our experiments, chondroadherin was released at intermediate to high levels immediately when culture was started, probably reflecting adaptation to culture conditions. The initially high levels of chondroadherin released decreased during pre-culture. Release was induced by the treatment with Fn-f. However, levels peaked on day 1 or 2 of stimulation, and decreased again at different rates. This pattern of release of chondroadherin would suggest a more rapid course for loss of chondroadherin than for loss of COMP. The absence of detectable chondroadherin levels in synovial fluid of RA and OA patients may reflect that this release is an event so early as to already have taken place when medical care is sought for joint disease. Thus, an intriguing question which remains to be further clarified concerns the timing and relation between chondroadherin release and that of COMP.
THE PRODUCTION OF NO
Stimulation of cartilage explant cultures with cytokine Interleukin-1 (IL-1) leads to the release of proteoglycan and production of nitric oxide (NO), a signalling molecule 48 . NO has been implicated in RA (for review, see 49 ). In our experiments, treatment with Fn-f Hep II has consistently given a reproducible dose-response curve (a total of 10 experiments), though the absolute values have varied. This may be due to different batches of reagent, or the stability of the Griess reagents. However, a positive control was always included in all experiments comparing NO production.
In our experiments, the Fn-f Hep II induced NO production in a dose-dependent manner, whereas the Fn-f Hep I did not. There are reports where Fn-f Hep I has been reported to stimulate NO production in monolayer culture of human primary chondrocytes 50 . However, the levels Our results show that co-incubation of Fn-f Hep II with heparin partially inhibits the response to the Fn-f Hep II fragment. The lower levels of COMP released may reflect either an inhibitory process where the effect of the Fn-f Hep II is partially blocked or an altered kinetics of release where release of COMP is slowed. This is in keeping with results from Yasuda et al 51 .
In their experiments, incubation with the heparin-binding peptide (WQPPRARI) blocks the production of MMPs induced by the Fn-f Hep II.
Fibronectin fragments have been shown to bind to the 5 integrin subunit, indicating that some fragments may interact with the 5 1 integrin to transduce their effects 52, 53 . However, our data suggest an additional receptor for other fibronectin fragments.
Inhibition of COMP release and degradation was achieved by co-incubation with a Src-kinase inhibitor, but not with an inhibitor of PKC kinases. Intriguingly, the release of chondroadherin is not affected by Src inhibition. It is possible that release of COMP and chondroadherin are the result of different signaling pathways.
THE FN-F HEP I
The Fn-f Hep I used here includes the 29-kDa fragment reported to be the most potent fragment of those used to stimulate bovine cartilage 14 . In our experiments however, this is not the case. On the contrary, though the Fn-f Hep I does seem to be able to elicit some degradation and release of COMP, it is less potent than the Fn-f Hep II.
RELEASE OF CARTILAGE COMPONENTS MAY BE USEFUL AS MARKERS FOR DISEASE
It is worth noting that there are interactions between the three molecules in focus here. COMP is found primarily pericellularly in adult cartilage, while in developing cartilage it is also found interterritorially, further away from the chondrocyte 54 . COMP can bind collagen 44 and the N-terminus of fibronectin 55 . Chondroadherin, a component of the pericellular compartment, can both bind collagen 47 and interact with the chondrocyte via the integrin 2 1 23 . This integrin is also a receptor for collagen 56, 57 . This network of interactions is but one of several such networks in existence in the matrix, where the components are linked to each other and ultimately link back to the chondrocyte. Even subtle disturbances of such a network in the matrix may lead to changes in interactions with cell surface receptors, and thereby effect a change in the signals to the chondrocyte from its surrounding matrix. The results shown may describe an example of early effects of disturbing such a network of interactions.
The degradation or incapacitation of the accessory molecules contributing to the integrity of the collagen network will likely precede an ultimate failure of the network. As the different components are affected at different times, it should be possible to monitor the progression of tissue destruction and the involvement of different compartments by demonstrating the degradation and release of extra cellular matrix molecules characteristic for a given compartment in the cartilage. Knowledge concerning the sequence of events would potentially be of great use in patient care for diagnosis, monitoring and estimation of prognosis. Elucidation of the responses reported here, in particular the timing and possibility of involvement of different signaling pathways, would be a valuable step on the way to understanding more fully the process of cartilage destruction in joint diseases. 
